Lu AA21004 Shows Highly Significant Results in Clinical Phase II Trial
COPENHAGEN, Oct. 2, 2007-H. Lundbeck A/S today announced
positive headline results from a newly unblinded proof of concept
clinical study with the compound Lu AA21004 for the treatment of
Major Depressive Disorder.
The clinical trial was a multicenter, double-blind,
placebo-controlled trial including 426 patients with major
depression. Lu AA21004 showed highly significant improvements on
the primary efficacy endpoints with both 5 and 10 mg compared to
placebo and had an attractive safety profile.
"We are pleased that the encouraging results from this proof of
concept study confirm our experimental expectations of Lu AA21004
as a potent and well tolerated new drug for the treatment of major
depression," says Anders Gersel Pedersen, Head of Development at
Lundbeck and continues: "Lu AA21004 is the most advanced project
within the new bis-aryl-sulphanyl amine class of compounds for the
treatment of mood disorders and anxiety, and we look forward to
further exploiting the potential of these novel
projects."
Lu AA21004 is jointly being developed by H. Lundbeck A/S and Takeda
Pharmaceutical Company Limited. Following analysis of the phase II
data, Lundbeck and Takeda will plan the next steps in the
development of Lu AA21004.
The content of this release will have no influence on the Lundbeck
Group's financial result for 2007.
Lundbeck contacts
Investors: Media:
Jacob Tolstrup Caroline Broge
Director, Investor Relations Media Relations Manager
+45 36 43 30 79 +45 36 43 26 38
+1 201 350 0187
